In Autumn 2020, DOAJ will be relaunching with a new website with updated functionality, improved search, and a simplified application form. More information is available on our blog. Our API is also changing.

Hide this message

Correlation Between Circulating Levels of Secreted Frizzled-Related Protein 5 and Type 2 Diabetic Patients and Subjects with Impaired-Glucose Regulation

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy. 2020;Volume 13:1243-1250

 

Journal Homepage

Journal Title: Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy

ISSN: 1178-7007 (Online)

Publisher: Dove Medical Press

LCC Subject Category: Medicine: Internal medicine: Specialties of internal medicine

Country of publisher: United Kingdom

Language of fulltext: English

Full-text formats available: PDF, HTML

 

AUTHORS


He X

Ma H

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 16 weeks

 

Abstract | Full Text

Xiaoyan He,1 Huijuan Ma2 1Special Medical Department, Beijing Jiangong Hospital, Beijing 100054, People’s Republic of China; 2Department of Endocrinology, Hebei General Hospital, Shijiazhuang 050051, People’s Republic of ChinaCorrespondence: Xiaoyan HeSpecial Medical Department, Beijing Jiangong Hospital, Beijing 100054, People’s Republic of ChinaEmail nongx[email protected]: Secreted frizzled-related protein 5 (SFRP5) is a recently identified adipokine; however, its functions during pathogenesis of T2DM and obesity remain unclear. This research attempted to investigate associations between circulating SFRP5 and obesity/T2DM.Materials and Methods: According to diagnosis, 107 patients were assigned as impaired-glucose regulation (IGR) and 111 patients newly-diagnosed as T2DM were assigned as the T2DM group. Meanwhile, 132 subjects with normal-glucose tolerance (NGT) were assigned as the NGT group. Differences in plasma SFRP5 levels among three groups were compared. Correlation between SFRP5 levels and different metabolic markers was analyzed. Multiple-linear stepwise regression analyses were performed to determine independent factors for SFRP5. Patients in the T2DM group were administrated with metformin for 12 weeks. Meanwhile, changes in plasma SFRP5 levels were also analyzed.Results: Plasma SFRP5 level of the IGR group was significantly lower compared to the NGT group (219.1± 39.7 pg/mL vs 236.7± 72.6 pg/mL, P< 0.05), however, that of the T2DM group was significantly lower compared to the IGR group (203.5± 42.1 pg/mL vs 219.1± 39.7 pg/mL, P< 0.01). Level of plasma SFRP5 was negatively correlated with fasting plasma glucose, BMI, waist circumference (WC), normalized WC (waist-to-height ratio) (WHtR), 2h plasma glucose, fasting insulin, glycosylated hemoglobin (HbA1c), fasting C-peptide, HOMA-IR, and hs-CRP (P< 0.01). Among the above factors, HbA1c and fasting insulin levels (FIns) were two independent factors. Plasma SFRP5 levels were increased after 12-week metformin treatment (201.0± 34.8 pg/mL vs 213.1± 34.4 pg/mL, P< 0.05), while insulin resistance was alleviated (ln(HOMA-IR): 1.35± 0.55 vs 1.07± 0.49, P< 0.01).Conclusion: Metformin reduced circulating levels of secreted frizzled-related protein 5 and improved pathophysiological parameters of T2DM.Keywords: secreted frizzled-related protein 5, type 2 diabetes mellitus, obesity, insulin resistance, metformin